ADAMTS13 Antibody Test
Test Mnemonic
ABADM
CPT Codes
- 83520 - QTY (1)
LOINC ®
40824-5
Includes
- ADAMTS13 Antibody (U/mL)
Performing Laboratory
Cleveland Clinic Laboratories
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Plasma | Sodium citrate (Lt. Blue) | Frozen |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Citrated plasma for ADAMSTS13 Antibody remain stable at room temperature and refrigerated for 7 days days,but no tests for ADAMSTS13 Activity or Inhibitor can be performed on those samples. |
Days Performed
Mon - Fri
Turnaround Time
2 - 4 days
Methodology
| Name | Description |
|---|---|
| Enzyme Immunoassay (EIA) |
Reference Range
| ADAMTS13 Antibody | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Years | 99 Years | Normal | <19 | U/mL |
Clinical Info
Thrombotic thrombocytopenia purpura (TTP) is a life-threatening hematological condition characterized by low platelet count, microvascular thrombi, red cell fragmentation, CNS and renal complications. Severe deficiency of ADAMTS-13 activity, either because of a congenital or an acquired etiology, has been shown to be a major cause of TTP. ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is also known as von Willebrand Factor (vWF) cleaving protease (VWFCP). It is a zinc-containing metalloproteinase that cleaves ultra large vWF multimers (ULvWF) at the Tyr(1605)-Met(1606) bond located in the A2 region of vWF. The ULvWF, if not cleaved, has the ability to bind platelets and trigger intravascular platelet aggregation and lead to thrombus formation. Anti-ADAMTS13 antibodies have been isolated in a number of TTP patients and are closely associated with idiopathic TTP. Most of these ADAMTS13 autoantibodies have inhibitory function of the ADAMTS13 enzymatic activity and thus can be measured by the ADAMTS13 inhibitor test (mixing study). However, the ADAMTS13 antibody test may detect some additional non-inhibitory antibodies. The ADAMTS13 antibody test, when using as a panel with the ADAMTS13 activity and inhibitor tests, should further help to characterize the disease and aid clinicians in the differential diagnosis of TTP and guide treatment selection.